Decidual Cells Produce a Heparin-binding Prolactin Family Cytokine with Putative Intrauterine Regulatory Actions*

S. M. Khorshed Alam, Toshihiro Konno, Namita Sahgal, Lu Lu, and Michael J. Soares1

From the Institute of Maternal-Fetal Biology and the Division of Cancer and Developmental Biology, Departments of Pathology and Laboratory Medicine and Obstetrics and Gynecology, University of Kansas Medical Center, Kansas City, Kansas 66160

Pregnancy in mice and rats is associated with the production of a large family of hormones/cytokines related to prolactin (PRL). The hormones/cytokines are hypothesized to coordinate maternal and fetal adaptations to pregnancy. In this study, PRL-like protein-J (PLP-J, also known as PRL family 3, subfamily c, member 1 (Prl3c1)) is shown to be a product of the uterine decidua and a regulator of postimplantation intrauterine events. PLP-J-specific antibodies and a series of recombinant PLP-J proteins were generated and used to investigate PLP-J expression and as ligands for investigating biological targets. Decidual PLP-J migrates as a 29-kDa protein and localizes to a band of decidual cells surrounding the trophoblast cell layer on gestation day 8.5. PLP-J ligands specifically bound in situ to the surrounding uterine stromal cells and vasculature within the decidua of gestation day 8.5 implantation sites. We then investigated the in vitro actions of PLP-J on uterine stromal cells and endothelial cells. PLP-J specifically interacted with both cell populations. PLP-J promoted uterine stromal cell proliferation and inhibited endothelial cell proliferation. We determined that PLP-J does not interact with PRL receptors. Instead, PLP-J interacts with heparin-containing molecules, including syndecan-1, which is expressed in gestation day 8.5 pregnant uteri, as well as in uterine stromal cells and endothelial cells. The restricted expression of PLP-J and its specific interactions with uterine stromal cells and endothelial cells suggests that it acts locally and regulates decidual cell development and the endometrial vasculature.

Successful pregnancy requires specialized maternal adaptations. Decidualization is a key uterine adaptation associated with the establishment of pregnancy and is characterized by the differentiation of uterine stromal cells (1–4). Decidual cell differentiation is dependent upon ovarian steroid hormone production, and in rodents, it also requires signals emanating from the preimplantation embryo (1, 5). Once formed, decidual cells establish a protective environment, facilitating the development of the placenta and embryo. They promote the redistribution of specific populations of leukocytes and reorganize the uterine vascular network. Intercellular signals elaborated by decidual cells are key mediators of these uterine adaptive responses. Among the decidual cell ligands are a family of cytokines related to prolactin (PRL).2

PRL is an ancient hormone with its origins as a regulator of vertebrate environmental adaptations (6, 7). Some species possess a single member of the PRL family that can be expressed in an assortment of tissues, including the anterior pituitary and uterus through the utilization of cell-specific promoters (8–10). Other species have undergone a gene expansion within the PRL locus (11). PRL family gene expansion is particularly robust in mice and rats (12–14). Gene duplication and natural selection have yielded 2 dozen related genes in each of these species. The PRL family genes encode cytokines/hormones that are expressed in cell-specific and temporally specific patterns and are most relevant to pregnancy-associated tissues, especially in the uterine decidua and the placenta. Initial observations suggest that the expanded PRL family participates in pregnancy-dependent adaptations to physiological stressors (15, 16). Although a few members are PRL mimetics (placental lactogens), activating PRL receptor signaling cascades, most utilize distinct strategies to regulate their cellular targets (11, 17). The cellular targets are intriguing and include endothelial cells, inflammatory/immune cells, and hematopoietic precursors (18–22).

Decidual cells of mice and rats express four members of the PRL family: PRL (23, 24), PRL-like protein-B (PLP-B; also known as PRL family 6, subfamily a, member 1 (Prl6a1)) (25–28), decidual PRL-related protein (dPRP; also known as PRL family 8, subfamily a, member 2 (Prl8a2)) (27, 29, 30), and PLP-J (also known as PRL family 3, subfamily c, member 1 (Prl3c1)) (31–34). PRL is postulated to be expressed in rodent decidual cells under the direction of a unique cell-specific promoter, as has been characterized for human decidual cells (10, 35), where it acts through the PRL receptor signaling pathway to promote decidual cell survival, regulate leukocyte function, stimulate uterine gland development, and facilitate vascular remodeling (23, 36–38). PLP-B and dPRP do not utilize the canonical PRL receptor signaling pathway (22, 26, 39). dPRP is a heparin-binding cytokine that is essential for pregnancy-dependent adaptive responses to hypoxia (16, 22, 39). Unlike wild-type animals,

1 To whom correspondence should be addressed: Institute of Maternal-Fetal Biology, Dept. of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS 66160. Fax: 913-588-8287; E-mail: msoares@kumc.edu.

2 The abbreviations used are: PRL, prolactin; DMEM, Dulbecco’s modified Eagle’s medium; FBS, fetal bovine serum; CHO, Chinese hamster ovary; NTA, nitritriacetic acid; AP, alkaline phosphatase; BSA, bovine serum albumin; FGF2, fetal growth factor 2; BrdUrd, bromodeoxyuridine.
PLP-J, a Decidual Heparin-binding Cytokine

mice deficient in dPRP do not effectively adapt to hypoxia and terminate their pregnancies. dPRP modulates decidual expression of PLP-J but not PLP-B or PRL (16). The expression of PLP-J is significantly decreased in dPRP null mice, suggesting that the biology of dPRP and PLP-J may be linked. Information on the biological functions of PLP-J is not available.

In this study, we have characterized the PLP-J protein and its expression pattern, identified targets for its action, and determined biological responses of its cellular targets. PLP-J is a heparin-binding cytokine with distinct actions on uterine stromal cell and endothelial cell populations.

EXPERIMENTAL PROCEDURES

Animals and Tissue Preparation

Holtzman rats were obtained from Harlan Sprague-Dawley Inc. (Indianapolis, IN). The animals were housed in an environmentally controlled facility, with lights on from 0600 to 2000 h and were allowed free access to food and water. Timed pregnancies were generated, and tissue dissections were performed as previously detailed (40). Conceptuses with associated uterine cervices were generated, and tissue dissections were performed for subsequent RNA and protein analyses. The presence of sperm in the vaginal smear was designated as day 0.5 of pregnancy. New Zealand White rabbits were obtained from Myrtle’s Rabbitry (Thompsons Station, TN) and used for antibody production. Protocols for the care and use of animals were approved by the University of Kansas Animal Care and Use Committee.

Cell Culture

U1 rat uterine stromal cells were obtained from Dr. Virginia Rider (Pittsburg State University, Pittsburg, KS) and maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1 mm sodium pyruvate, and penicillin (100 units/ml) and streptomycin (100 µg/ml) (41, 42). These rat uterine stromal cells are physiologically relevant in that they can be induced to differentiate into decidual cells (43). Rat aortic endothelial cells were purchased from VEC Technologies, Inc. (Rensselaer, NY) and maintained in MCDB-131 complete culture medium. The rat Nb2 lymphoma cell line was provided by Dr. Peter Gout (University of British Columbia, Vancouver, Canada) and maintained in RPMI 1640 culture medium supplemented with 10% horse serum, 10% FBS, 50 µM 2-mercaptoethanol, 2 mM l-glutamine, 5 mM HEPES, penicillin (50 units/ml), and streptomycin (50 µg/ml) (44). Human embryonic kidney (HEK 293) cells were obtained from ATCC (Manassas, VA) and used as a host for the expression of the PLP-J fusion proteins. HEK 293 cells were maintained in DMEM/F-12 medium supplemented with 10% FBS, 1 mm sodium pyruvate, penicillin (100 units/ml), and streptomycin (100 µg/ml). CHO cells and heparan sulfate-deficient CHO-pgsD-677 cells were obtained from ATCC and cultured in DMEM/MCDB 302 culture medium containing 100 units/ml penicillin, 100 µg/ml streptomycin, and 10% FBS. Raji cells stably transfected with a syndecan-1 (Sdc1) expression vector (Raji-S1) and the parent Raji cell line were obtained from Dr. Alan C. Rapraeger (University of Wisconsin, Madison, WI) and were maintained in RPMI 1640 culture medium supplemented with 10% FBS and antibiotics (45). All cell cultures were maintained in a humidified atmosphere of 5% CO₂, 95% air at 37 °C.

Generation of Fusion Proteins

mFLAG-PLP-J—PLP-J was expressed as a fusion protein with a FLAG-His₅-FLAG tag. The full-length mature rat PLP-J cDNA was used as a template for PCR amplification of a PLP-J fragment with EcoRI and XbaI restriction sites at the 5’- and 3’-ends, respectively, using sequence specific primers, 5’-cat tta aag aat tca cac cat atg acc aga tgt-3’ and 5’-gtt ata tgt ttc tag acc act tgt taa ta-3’. After digestion with EcoRI and XbaI restriction enzymes, the fragment was ligated into a modified pFLAG-CMV-3 vector (mFLAG; Sigma). The accuracy of vector construction was verified by DNA sequencing. The mFLAG-PLP-J plasmid was transfected into HEK 293 cells using Lipofectamine Plus according to the manufacturer’s instructions (Invitrogen). The initial selection of transfected cells was accomplished in the presence of G418 at a concentration of 500 µg/ml. Selected cells were then maintained in 100 µg/ml G418.

The mFLAG-PLP-J fusion protein was purified from serum-free conditioned medium by incubating with an Ni²⁺-NTA-agarose resin (Qiagen, Valencia, CA). In brief, Ni²⁺-NTA-agarose was equilibrated with Sorensen’s phosphate buffer (NaH₂PO₄ (66 mM) and KH₂PO₄ (66 mM)) and added to conditioned medium in a buffer containing 10 mM imidazole, 50 mM NaH₂PO₄, 0.15 M NaCl, pH 8.0 (1× binding buffer), incubated overnight at 4 °C with constant shaking. The resin was then transferred into a column and washed with 2× binding buffer. Recombinant mFLAG-PLP-J protein was eluted with 250 mM imidazole and 0.15 M NaCl in Sorensen’s phosphate buffer, pH 6.0. Aliquots of fractions were separated using SDS-PAGE and stained with Coomassie Blue G-250 and immunoblotted with anti-FLAG M2 antibody (Sigma). Immunopositive fractions were pooled and dialyzed against phosphate-buffered saline, pH 7.4, and concentrated by Centricron ultrafiltration centrifugation devices (Millipore, Billerica, MA). Purified proteins were sterilized using Millex filters (Millipore), and concentrations were determined with the DC protein assay (Bio-Rad).

Alkaline Phosphatase (AP)-PLP-J Fusion Protein (AP-PLP-J)—The full-length cDNA for mature rat PLP-J was ligated downstream of heat-stable human placental AP of pcMV-SEAP and then transfected into HEK 293 cells, as previously described (46, 47). The transfected cells were selected and maintained in DMEM/F-12 culture medium supplemented with 10% FBS and G418 as described above. Cells were transfected to serum-free culture medium for 72 h. Conditioned medium was collected, and cellular debris was removed by centrifugation at 2,200 × g for 30 min at 4 °C and then stored at −20 °C. AP activity was quantified by a colorimetric assay at 405 nm using p-nitrophenyl phosphate as an AP substrate (47). AP fusion proteins were also separated using SDS-PAGE and electrophoretically transferred to nitrocellulose, and AP activity was detected by incu-
JOURNAL OF BIOLOGICAL CHEMISTRY

**expression patterns of dPRP mRNA (and protein were localized to decidual cells surrounding the developing embryo in distributions similar to the specificity of the immunoreactivity was determined by competing with purified mFLAG-PLP-J (and 5'-ggt atg cta tgt cca gcc caa acc acc tga tgt-3' and 5'-ggt atg cta tgt cca gcc ctt acc act tgt ttt taa taag-3'). The amplified fragment was ligated into the pQE-30Xa plasmid and transformed into *Escherichia coli*, M15[pREP4]. His<sub>s</sub>-PLP-J expression was induced by 2 mM isopropyl-β-D-1-thiogalactopyranoside, and His<sub>s</sub>-PLP-J protein was purified from bacterial exclusion bodies by Ni<sup>2+</sup>-NTA-agrose affinity chromatography, as described above. Purified His<sub>s</sub>-PLP-J was characterized by SDS-PAGE and Western blotting with anti-His tag antibodies (Qiagen). Purified His<sub>s</sub>-PLP-J was used to immunize New Zealand White rabbits as previously described (48, 49).

**Western Blot Analysis of Decidual Tissues**

Protein lysates were prepared by homogenizing gestation day 8.5 rat conceptuses (decidua and extraembryonic and embryonic tissues) in radioimmune precipitation buffer (10 mM Tris-HCl, pH 7.2, 1% Triton X-100 or 1% Nonidet P-40, 1% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 5 mM EDTA, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 10 μg/ml aprotinin). Protein concentrations were determined by the DC protein assay (Bio-Rad). Fifty μg of total protein were separated by SDS-PAGE and transferred onto nitrocellulose membranes. Immunoreactive PLP-J and dPRP were detected with antibodies to anti-PLP-J (present study) and anti-dPRP (39), respectively, and visualized by enhanced chemiluminescence according to the manufacturer’s instructions (Amersham Biosciences).

**Immunocytochemistry**

Immunocytochemical analyses were used to localize PLP-J and dPRP proteins and the distribution of endothelial cells in gestation day 8.5 implantation sites, as described (39, 40, 50). Cryosections (10 μm) were prepared, fixed in cold 4% paraformaldehyde solution, and blocked in 10% normal goat serum for 1 h at room temperature. The immunodetection was performed by incubating overnight at 4 °C with anti-PLP-J (present study), anti-dPRP antibodies (39), or RECA-1 antibodies, which recognize an uncharacterized rat endothelial cell-specific surface antigen (Sorotec, Oxford, UK) (41). Avidin-peroxidase-conjugated secondary antibody was added for 30 min at room temperature and color-developed with an AEC kit (Zymed Laboratories, San Francisco, CA). Tissues were counterstained with Mayer’s
hematoxylin. Images were captured using a Leica MZFLIII stero-microscope (Leica Microsystems GmbH, Wetzlar, Germany) or a Nikon Eclipse 55i microscope (Nikon Instruments Inc., Melville, NY), both equipped with Leica CCD cameras (Leica).

**In situ Hybridization**

In situ hybridization was performed to assess the distributions of PLP-J and dPRP transcripts in gestation day 8.5 rat implantation sites (40, 51). Cryosections (10-μm) were prepared and stored at −80 °C until use. Plasmids containing cDNAs for PLP-J (34) and dPRP (29) were used as templates to synthesize sense and antisense digoxigenin-labeled riboprobes according to the manufacturer’s instructions (Roche Applied Science). The frozen sections were air-dried and fixed in cold 4% paraformaldehyde in phosphate-buffered saline. Prehybridization, hybridization, and detection of alkaline phosphatase-conjugated anti-digoxigenin were performed as previously reported (12, 51). Images were captured as described above.

**Northern Blot Analysis**

Northern blot analysis was performed as previously described (52). Total RNA was extracted from gestation day 8.5 rat decidual tissues, U1 uterine stromal cells, and rat aortic endothelial cells using TRIzol reagent (Invitrogen). Total RNA was extracted from gestation day 8.5 tissues—An in situ AP-binding assay was performed as previously described (46, 47). In brief, 8–10-μm tissue sections were prepared with a cryostat and mounted onto glass slides. The tissue sections were washed with a modified Hanks’ balanced salt solution (HBHA containing 20 mm HEPES, 0.5 mg/ml BSA and 0.1% NaN3) and incubated with AP, AP-PLP-J, or AP-placental lactogen-I (PL-I; also known as PRL family 3, subfamily d, member 1 (Prl3d1)) fusion protein (46) for 75 min at room temperature. For competition, tissue sections were incubated with various glycosaminoglycans and/or mFLAG-PLP-J fusion protein (46) for 75 min at room temperature. Following incubation, tissue sections were washed three times with HBHA containing 0.1% Tween 20 and fixed for 20 min with acetone-formaldehyde fixative. The fixed sections were mounted onto glass slides. The tissue sections were washed with a modified Hanks’ balanced salt solution (HBHA containing 20 mm HEPES, 0.5 mg/ml BSA and 0.1% NaN3) and incubated with AP, AP-PLP-J, or AP-placental lactogen-I (PL-I; also known as PRL family 3, subfamily d, member 1 (Prl3d1)) fusion protein (46) for 75 min at room temperature. For competition, tissue sections were incubated with various glycosaminoglycans and/or mFLAG-PLP-J protein for 45 min prior to incubation with AP-PLP-J. Following incubation, tissue sections were washed three times with HBHA containing 0.1% Tween 20 and fixed for 20 min with acetone-formaldehyde fixative. The fixed sections were washed and heated at 65 °C for 30 min to inactivate endogenous AP activity in the tissues. Localization of AP was determined by incubation with nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate.

**Heparin Binding Assay**

PLP-J and dPRP interactions with heparin were evaluated with a heparin-binding plate assay (55). Multiwell plates were coated with either heparin conjugated to bovine serum albumin (heparin-BSA; Sigma) or BSA (Sigma) and incubated with AP-PLP-J, AP-dPRP, or AP. Wells were washed with HBHA containing 0.1% Tween 20 and HBSS. AP activity was determined by incubation with AP substrate (p-nitrophenyl phosphate) and measurement of absorbance at 405 nm. AP-PLP-J binding to heparan sulfate-deficient CHO-pgsD-677 cells and wild-type CHO cells was also assessed as previously described (22). AP-PLP-J and AP-PL-I binding with the PRL receptor were assessed in CHO-pgsD-677 cells (53) transiently transfected with the PRL receptor (pECE/long; gift from Dr. Paul Kelly, INSERM, Paris, France) (54) using FusGene 6 (Roche Applied Science). The AP-PL-I fusion protein was used as a positive control.

**Cell Adhesion Assay**

Cell adhesion assays were performed as described (56). 96-well microtiter plates were coated with test proteins diluted in PBS (50 μl/well) and incubated at 4 °C for 16 h. Wells were washed three times with PBS and blocked with 1% BSA at room temperature for 1 h. To test for specificity, anti-PLP-J serum or normal rabbit serum was added to the wells and incubated for 1 h at 37 °C prior to plating of cells. Cells were harvested in normal growth medium, washed with HBSS, and resuspended at 5 × 10^5 cells/ml in serum-free normal growth medium. Where indicated, cells were incubated with heparin prior to plating for 1 h at room temperature. A 50-μl cell suspension was added to each well and incubated 30 min at 37 °C. Adherent cells were fixed in 10% formalin in saline for 30 min at room temperature. The cells were stained with methylene blue, and adhesion was quantified by dye extraction and measurement of absorbance at 620 nm (56).

**PLP-J, a Decidual Heparin-binding Cytokine**

PLP-J and dPRP interactions with heparin were evaluated with a heparin-binding plate assay (55). Multiwell plates were coated with either heparin conjugated to bovine serum albumin (heparin-BSA; Sigma) or BSA (Sigma) and incubated with AP-PLP-J, AP-dPRP, or AP. Wells were washed with HBHA containing 0.1% Tween 20 and HBSS. AP activity was determined by incubation with AP substrate (p-nitrophenyl phosphate) and measurement of absorbance at 405 nm.

**Cell Adhesion Assay**

Cell adhesion assays were performed as described (56). 96-well microtiter plates were coated with test proteins diluted in PBS (50 μl/well) and incubated at 4 °C for 16 h. Wells were washed three times with PBS and blocked with 1% BSA at room temperature for 1 h. To test for specificity, anti-PLP-J serum or normal rabbit serum was added to the wells and incubated for 1 h at 37 °C prior to plating of cells. Cells were harvested in normal growth medium, washed with HBSS, and resuspended at 5 × 10^5 cells/ml in serum-free normal growth medium. Where indicated, cells were incubated with heparin prior to plating for 1 h at room temperature. A 50-μl cell suspension was added to each well and incubated 30 min at 37 °C. Adherent cells were fixed in 10% formalin in saline for 30 min at room temperature. The cells were stained with methylene blue, and adhesion was quantified by dye extraction and measurement of absorbance at 620 nm (56).
**PLP-J, a Decidual Heparin-binding Cytokine**

**Nb2 Lymphoma Cell Proliferation Assay**

The Nb2 lymphoma cell proliferation assay was performed with some modifications to the previously published procedure (44). Twenty-four h before initiating the assays, cells were incubated with RPMI1640 supplemented with 5% horse serum, 2 mM L-glutamine, 5 mM HEPES, and antibiotics (Assay Medium) to establish a quiescent state. Cells were washed with Assay Medium, counted with a hemocytometer, and distributed to wells in a 96-well plate ($2.5 \times 10^4$ cells/well). Cells were incubated with ovine PRL (0.1, 1, or 10 ng/ml; NOBL Laboratories, Inc., Sioux Center, IA) or mFLAG-PLP-J (0.1, 1, or 10 µg/ml) for 72 h. Viable cells were quantified by the CellTiter 96 AQ~sous~ nonradioactive cell proliferation assay (Promega, Madison, WI).

**Rat Uterine Stromal Cell Proliferation Assay**

Rat U1 uterine stromal cells were harvested by trypsin-EDTA, washed, and resuspended in DMEM supplemented with 10% FBS, 1 mM sodium pyruvate, and 100 units/ml penicillin and 100 µg/ml streptomycin. Cells were distributed in 96-well plates at a density of $1 \times 10^3$ cells/well and incubated for 24 h. To initiate the assays, cells were starved for 24 h with DMEM medium containing 1% FBS. Cells were then treated with mFLAG-PLP-J (0.01, 0.1, 1, or 10 µg/ml) or fibroblast growth factor 2 (FGF2; 10 ng/ml; R&D Systems, Minneapolis, MN) for 24, 48, or 72 h. Numbers of viable cells were measured by the CellTiter 96 AQ~sous~ nonradioactive cell proliferation assay (Promega) at the indicated times. To assess DNA synthesis, cells were grown as described above and distributed in 24-well plates. Bromodeoxyuridine (BrdUrd; Sigma) was added to the medium (10 µM) for 16 h in the presence or absence of mFLAG-PLP-J. The BrdUrd incorporation was detected using a BrdUrd staining kit (BD Pharmingen).

**Endothelial Cell Proliferation Assay**

Rat aortic endothelial cells were harvested by trypsin-EDTA, washed, and resuspended in complete MCDB-131 medium. The cells were distributed in 48-well plates at a density of $4 \times 10^3$ cells/well and incubated for 24 h. To initiate the experiments, cells were incubated with MCDB-131 basal medium with 1% FBS for another 24 h. Cells were then treated with different concentrations of mFLAG-PLP-J (0.01, 0.1, 1, or 10 µg/ml) or FGF2 (10 ng/ml) for 24, 48, and 72 h. The numbers of viable cells were measured using the CellTiter 96 AQ~sous~ nonradioactive cell proliferation assay (Promega). The effects of PLP-J on endothelial cell DNA synthesis were determined with the BrdUrd incorporation assay as described above.

**Cell Proliferation Monitored by Crystal Violet Staining**

Proliferation indices of U1 rat uterine stromal cells and rat aortic endothelial cells were also evaluated morphologically by crystal violet staining, as previously described (57, 58). Cells were harvested with trypsin-EDTA, washed, resuspended at $5 \times 10^4$ cells/ml in growth medium, distributed in 48-well plates, and cultured for 24 h. Cells were washed and preincubated with medium containing 1% FBS for 24 h. Test proteins were then added to the cells. At the indicated time intervals, cells were stained with 0.1% crystal violet for 10 min, washed with distilled water, and dried at room temperature. Images of cells were captured with a Leica MZFIII stereomicroscope equipped with a CCD camera (Leica).
PLP-J, a Decidual Heparin-binding Cytokine

Statistical Analysis

Statistical comparisons between two means were determined with Student's t test. Comparisons among multiple means were evaluated with analysis of variance. The source of variation from significant F-ratios was determined with Bonferroni's multiple comparison test (59).

RESULTS

Generation of PLP-J Fusion Proteins and Antibodies—PLP-J was engineered to be expressed in recombinant form containing FLAG and His6 tags at its N terminus (mFLAG-PLP-J) in HEK 293 cells. Purified mFLAG-PLP-J consisted of three species with molecular masses ranging from ~31 to 37 kDa (Fig. 1A). PLP-J possesses two putative N-linked glycosylation sites (31–34); thus, differential glycosylation may account for the mFLAG-PLP-J size variants. mFLAG-PLP-J was used as a ligand to evaluate PLP-J cellular actions (see below). PLP-J was also expressed as a His6-tagged fusion protein in a bacterial expression system. The His6-tagged PLP-J fusion protein migrated predominantly as a 26-kDa protein (Fig. 1B) and was used as an immunogen in rabbits. PLP-J antibodies reacted with both the mFLAG-PLP-J and His6-tagged PLP-J fusion proteins (Fig. 1, A and B). AP and AP-PLP-J fusion proteins were generated in HEK 293 cells (Fig. 1C) and used as probes to assess PLP-J interactions with putative cellular and molecular targets.

Intrauterine PLP-J Expression and Binding—PLP-J expression patterns and PLP-J targets were investigated. The distributions of PLP-J and dPRP mRNAs within the uterus of pregnant rats were assessed by in situ hybridization and were consistent with earlier reports (29, 30, 32, 34). PLP-J and dPRP mRNAs were predominantly observed in the uterine decidua, especially within the antimesometrial decidua (Fig. 2, A and D). PLP-J and dPRP protein immunolocalizations mirrored the distribution of PLP-J and dPRP mRNAs (Fig. 2, B and E). Decidual PLP-J migrated as a single 29-kDa protein and thus differed from the multiple molecular species of recombinant HEK 293 cell-engineered mFLAG-PLP-J (Fig. 2F). The specificity of the PLP-J immunoreactivity was demonstrated by competition with purified mFLAG-PLP-J (Fig. 2, C and F, lanes 2 and 4). PLP-J interactions with structures within gestation day 8.5 implantation sites were also investigated (Fig. 3). AP-PLP-J binding was detected throughout the uterus and was particularly evident in association with the uterine vasculature (Fig. 3, B–D and F–H) and the undifferentiated uterine stromal cell compartment (Fig. 3D). Intrauterine distributions of AP-PLP-J binding and RECA-1 immunoreactivity (a rat endothelial cell-specific antibody) overlapped. Intrauterine AP-PLP-J binding was specific (Fig. 3, J and K) and could be competed by mFLAG-PLP-J (Fig. 3K), heparin (Fig. 3L), heparan sulfate (Fig. 3M), and dermatan sulfate (Fig. 3O) but not chondroitin sulfate A or C (Fig. 3, N and P). In summary, PLP-J protein is synthesized by uterine decidual cells situated proximal to the developing embryo and specifically interacts with intrauterine structures, especially the vasculature and undifferentiated uterine stromal cells, in a heparin/heparan sulfate- and/or dermatan sulfate-dependent manner.

PLP-J Interacts with Heparin—Based on the heparin-dependence of the AP-PLP-J-uterine tissue binding, we further investigated PLP-J-heparin interactions. dPRP, another decidual cell cytokine, also specifically interacts with heparin (22, 39) and was used as a positive control in some of the analyses. AP-PLP-J and AP-dPRP specifically bound heparin-BSA-coated plates but not BSA-coated plates, whereas AP did not bind to either plate (Fig. 4A). AP-PLP-J also exhibited binding to CHO cells that was dependent upon the presence of heparan sulfate (Fig. 4, B and C). Additional PLP-J-cellular interactions that are potentially physiologically relevant (uterine stromal cells and endothelial cells; see Fig. 3) were assessed. AP-PLP-J specifically interacted with both uterine stromal cells (Fig. 5A) and endothelial cells (Fig. 5C). Heparin was an effective competitor of AP-PLP-J binding to uterine stromal cells (Fig. 5B) but was less effective in competing with AP-PLP-J binding to endothelial...
PLP-J, a Decidual Heparin-binding Cytokine

Collectively, the results indicate that PLP-J associates with heparin-containing molecules, potentially located in extracellular matrices and on cell surfaces.

PLP-J Interacts with Syndecans—Syndecans are a family of four transmembrane proteins possessing heparan sulfate sugar chains associated with their extracellular domains (60, 61). They have been implicated in cell adhesion and growth factor signal transduction and were considered molecular candidates for PLP-J interaction with its target cells. Initially, uterine decidua, uterine stromal cells, and endothelial cells were assessed for their expression of syndecan family members by Northern blotting (Fig. 6A). Gestation day 8.5 uterine decidua expressed Sdc1 and Sdc4 mRNAs, whereas uterine stromal cells and endothelial cells expressed only Sdc1 mRNA. Sdc2 and Sdc3 were not detected in decidua and the two cell populations. Raji cells are devoid of heparan containing molecules on their surfaces and represent a useful cell model for testing the biology of specific heparan sulfate proteoglycans (45). The ability of PLP-J to bind syndecans was evaluated in Raji cells genetically engineered to express Sdc1 (45). AP-PLP-J interactions with Raji cells were shown to be dependent upon the surface expression of Sdc1 (Fig. 6B). Thus, syndecans are expressed in the uterine decidua and are potential mediators of PLP-J-cellular interactions.

PLP-J Does Not Activate the Canonical PRL Receptor Signaling Pathway—A subset of members of the PRL family influence target cell function through activation of the PRL receptor signaling pathway (11). This subset includes PRL, PL-I, and PL-II (also known as PRL family 3, subfamily b, member 1 (Prl3b1)). Interestingly, PLP-J is also a member of the PL-I and PL-II subfamily. Its interactions with the PRL receptor signaling pathway...
PLP-J, a Decidual Heparin-binding Cytokine

were evaluated in the next series of experiments. Initially, binding experiments were performed with heparan sulfate-deficient CHO-pgsD-677 cells transfected with an expression vector containing the long form of the rat PRL receptor. AP-PL-I effectively interacted with the engineered cells, whereas AP-PL-P was most impressive after 72 h of incubation (Figs. 9A–C). Uterine stromal cell and endothelial cell proliferation were investigated with three complementary assays (Figs. 9A and 10). PLP-J modulated uterine stromal cell and endothelial cell proliferation. The effects of PLP-J in modulating uterine stromal cell and endothelial cell proliferation were investigated with three complementary assays (Figs. 9 and 10). PLP-J stimulated uterine stromal cell proliferation (Fig. 9, A–E) and uterine stromal cell incorporation of BrdUrd (Fig. 9F). In contrast, PLP-J inhibited endothelial cell proliferation and endothelial cell incorporation of BrdUrd (Fig. 10F). The effects of PLP-J on its cellular targets were most impressive after 72 h of incubation (Figs. 9C and 10C). The minimal effective PLP-J concentration was 1 μg/ml (Figs. 9B and C) and 10 (B and C). PLP-J also inhibited FGF2-stimulated endothelial cell proliferation (Fig. 10G). In summary, PLP-J stimulates uterine stromal cell proliferation and inhibits endothelial cell proliferation.
PLP-J, a Decidual Heparin-binding Cytokine

PLP-J interacts with and regulates specific cellular constituents of the uterus. Stromal cells and endothelial cells are among the putative intrauterine PLP-J targets. PLP-J can promote uterine stromal and endothelial cell adhesion. These interactions are mediated, at least in part, through heparin-containing molecules. Heparin-containing molecules are prominently displayed on the plasma membrane of cells and within the extracellular matrices of tissues (64). These molecules modulate development and are disrupted in some disease processes. PLP-J may not discriminate and instead associate with any uterine cell type possessing surface heparan sulfate proteoglycans in its proximity. Stromal cells and endothelial cells are prominent components of the preimplantation uterus, which undergo marked changes following embryo implantation (3, 5). Stromal cells serve as precursors for decidual cell differentiation, and endothelial cells line the intrauterine vasculature. During the establishment of pregnancy in mice and rats, the intrauterine vasculature undergoes specific regional modifications (3, 5, 65). Blood vessels in the mesometrial compartment (site of the developing chorioallantoic placenta) are significantly expanded in comparison with the anti-mesometrial uterine vasculature. In our in vitro analysis, PLP-J differentially affected the behavior of uterine stromal cells and endothelial cells. PLP-J stimulated proliferation of uterine stromal cells while inhibiting the proliferation of endothelial cells. These results indicate that PLP-J is a biologically active cytokine with the potential to regulate the intrauterine environment. The in vivo biological impact of decidual cell PLP-J production will be influenced by its access to its cellular targets and its relative contribution to the milieu of other growth factors and cytokines elaborated at the uteroplacental interface.

Relevant biologically active concentrations are difficult to determine for PLP-J. The heparin-binding properties of PLP-J will direct PLP-J to the cell surface or extracellular matrix, where it will have a juxtacrine mode of action. Thus, in an in vivo setting, PLP-J is sequestered and requires liberation from its tether to find its targets, or alternatively, the cellular targets may have to be brought to the sequestered PLP-J.

PLP-J modulates cell activities through mechanisms that are not yet defined. Some insights about PRL family member activation of signal transduction cascades are available. A subgroup of PRL family members (PRL, PL-I, and PL-II) utilizes the canonical PRL receptor signaling pathway (11). Among all members of the PRL family, PLP-J is most similar in amino acid sequence to the placental lactogens (31–34); however, PLP-J does not bind to or activate the PRL receptor (present study).

FIGURE 10. PLP-J inhibits endothelial cell proliferation. Endothelial cell proliferative responses to PLP-J were assessed by nonradioactive cell proliferation assay (A–C), crystal violet staining (D and E), and BrdUrd incorporation (F). Proliferative responses were evaluated at 24 h (A), 48 h (B), and 72 h (C) and expressed as absorbance at 590 nm. FGF2 (10 ng/ml) was used as a positive control. Values represent the mean ± S.E. of five replicates and are representative of three independent experiments. D and E, endothelial cells were treated with or without PLP-J (5 μg/ml) for 72 h and stained with 0.1% crystal violet. After washing, images were captured. F, effects of PLP-J on endothelial cell incorporation of BrdUrd. Cells were incubated in the presence of BrdUrd with or without PLP-J (5 μg/ml) for 16 h. BrdUrd-labeled cells were identified with a BrdUrd detection kit (BD Pharmingen). Results are expressed as the percentage of BrdUrd-stained cells versus the total number cells. G, endothelial cells were treated with vehicle (Ctrl), PLP-J (5 μg/ml), FGF2 (10 ng/ml), or FGF2 (10 ng/ml) plus PLP-J (5 μg/ml) for 72 h, and proliferation was assessed by a nonradioactive cell proliferation assay. All values represent the mean ± S.E. of five replicates. Asterisks indicate significant differences from controls (p < 0.01).

DISCUSSION

Evidence is accumulating for the involvement of the PRL family of cytokines in the regulation of maternal adaptations to pregnancy (11). In this report, we provide insights into a role for PLP-J, a member of the PRL family, in controlling intrauterine events during the establishment of pregnancy. The PLP-J protein was characterized, and its molecular and cellular interactions were investigated. PLP-J is expressed in uterine decidual cells and is a heparin-binding cytokine with potential paracrine actions on stromal and vascular cell development.

PLP-J is an intrauterine cytokine. The PLP-J protein is localized to a subpopulation of decidual cells situated proximal to the developing embryo (present study). This observation is consistent with earlier reports on PLP-J mRNA expression patterns (31–34). The decidual PLP-J protein has a molecular size of ~29 kDa and possesses heparin-binding properties. The expression profile and heparin binding features are also characteristics of another decidual PRL family cytokine, dPRP (22, 27, 29, 30, 39). PLP-J expression is also positively modulated by dPRP (16). This relationship may be indirect through dPRP activation of signal transduction cascades are available. A subgroup of PRL family members (PRL, PL-I, and PL-II) utilizes the canonical PRL receptor signaling pathway (11). Among all members of the PRL family, PLP-J is most similar in amino acid sequence to the placental lactogens (31–34); however, PLP-J does not bind to or activate the PRL receptor (present study).

PLP-J interacts with and regulates specific cellular constituents of the uterus. Stromal cells and endothelial cells are among the putative intrauterine PLP-J targets. PLP-J can promote uterine stromal and endothelial cell adhesion. These interactions are mediated, at least in part, through heparin-containing molecules. Heparin-containing molecules are prominently displayed on the plasma membrane of cells and within the extracellular matrices of tissues (64). These molecules modulate development and are disrupted in some disease processes. PLP-J may not discriminate and instead associate with any uterine cell type possessing surface heparan sulfate proteoglycans in its proximity. Stromal cells and endothelial cells are prominent components of the preimplantation uterus, which undergo marked changes following embryo implantation (3, 5). Stromal cells serve as precursors for decidual cell differentiation, and endothelial cells line the intrauterine vasculature. During the establishment of pregnancy in mice and rats, the intrauterine vasculature undergoes specific regional modifications (3, 5, 65). Blood vessels in the mesometrial compartment (site of the developing chorioallantoic placenta) are significantly expanded in comparison with the anti-mesometrial uterine vasculature. In our in vitro analysis, PLP-J differentially affected the behavior of uterine stromal cells and endothelial cells. PLP-J stimulated proliferation of uterine stromal cells while inhibiting the proliferation of endothelial cells. These results indicate that PLP-J is a biologically active cytokine with the potential to regulate the intrauterine environment. The in vivo biological impact of decidual cell PLP-J production will be influenced by its access to its cellular targets and its relative contribution to the milieu of other growth factors and cytokines elaborated at the uteroplacental interface.

Relevant biologically active concentrations are difficult to determine for PLP-J. The heparin-binding properties of PLP-J will direct PLP-J to the cell surface or extracellular matrix, where it will have a juxtacrine mode of action. Thus, in an in vivo setting, PLP-J is sequestered and requires liberation from its tether to find its targets, or alternatively, the cellular targets may have to be brought to the sequestered PLP-J.

PLP-J modulates cell activities through mechanisms that are not yet defined. Some insights about PRL family member activation of signal transduction cascades are available. A subgroup of PRL family members (PRL, PL-I, and PL-II) utilizes the canonical PRL receptor signaling pathway (11). Among all members of the PRL family, PLP-J is most similar in amino acid sequence to the placental lactogens (31–34); however, PLP-J does not bind to or activate the PRL receptor (present study).
PLP-J, a Decidual Heparin-binding Cytokine

Apparently, the critical amino acids dictating PRL receptor recognition are not present in PLP-J. Other differences from its closest relatives (PL-I and PL-II) are also evident. PLP-J possesses a domain(s) facilitating interactions with heparin-containing molecules. This ligand-directed heparin binding may be a key to understanding the cellular actions of PLP-J. Some heparan sulfate proteoglycans, such as syndecans, are transmembrane proteins capable of interacting with heparin-binding growth factors and mediating the activation of signal transduction cascades. The actions of other heparin-binding growth factors (e.g. fibroblast growth factors) that utilize transmembrane heparan sulfate proteoglycans. Differential expression of heparan sulfate proteoglycans could be responsible for the distinct effects of PLP-J on uterine stromal cells versus endothelial cells. Components of PLP-J activities were independent of interactions with heparin-containing molecules, suggesting that there may be additional modes of PLP-J action for some of its cellular targets. Among these may be interactions with specific membrane-associated receptor signaling pathways or possibly other glycosaminoglycans, including dermatan sulfate. PLP-J is capable of interacting with dermatan sulfate, and the uterine endometrium possesses dermatan sulfate proteoglycans. However, possible roles for dermatan sulfate proteoglycans in modulating PLP-J signaling have yet to be determined.

The PRL gene family expanded during the evolution of rodents (11, 17). New genes were derived from an ancestral template, which encode hormones and cytokines that are linked to viviparity and reproductive adaptations. PLP-J is part of the expanded rodent PRL family. It possesses a unique intracellular domain and a novel intracellular mode of action that is mediated, at least in part, through interactions with heparan sulfate proteoglycans.

Acknowledgments—We acknowledge the technical assistance of Chunbin Li and acknowledge the generous gifts of the U1 cell line from Dr. Virginia Rider, the Nb2 cell line from Dr. Peter Gout, the Raji cell line from Chunbin Li and acknowledge the generous gifts of the U1 cell line from Dr. Paul A. Kelly.

REFERENCES

1. DeFeo, V. J. (1967) in Cellular Biology of the Uterus (Wynn, R. M., ed) pp. 191–220, Appleton-Century-Crofts, New York
2. Aplin, J. (2000) Semin. Cell Dev. Biol. 11, 115–125
3. Bell, S. C. (1983) Mol. Endocrinol. 5, 20–27
4. Brosens, I. J., and Gellersen, B. (2006) J. Mol. Endocrinol. 36, 389–398
5. Parr, M. B., and Parr, E. L. (1989) in Biology of the Uterus (Wynn, R. M., and Jollie, W. P., eds) pp. 233–278, Plenum Press, New York
6. Bern, H. A., and Nicoll, C. S. (1968) Rec. Prog. Horm. Res. 24, 681–720
7. Nicoll, C. S., and Bern, H. A. (1972) in Lactogenic Hormones (Wolstenholme, G. E. W., and Knight, J., eds) pp. 299–338, Churchill Livingstone, London
8. DiMatti, G. E., Gellersen, B., Duckworth, M. L., and Friesen, H. G. (1990) J. Biol. Chem. 265, 16412–16421
9. Ben-Jonathan, N. B., Mershon, J. L., Allen, D. L., and Steinmetz, R. W. (1996) Endocrinology 132, 551–557
10. Hiraoka, Y., Ogawa, M., Sakai, Y., Takeuchi, Y., Komatsu, N., Shiozawa, K., Takebayashi, K., Ishikawa, H., Goto, S., and Noda, Y. (2001) J. Biol. Chem. 276, 1581–1584
11. Croze, F., Kennedy, T. G., Schroetter, I. C., and Friesen, H. G. (1990) Endocrinology 131, 2665–2672
12. Cohick, C. B., Xu, L., and Soares, M. J. (1997) J. Biol. Chem. 152, 291–302
13. Lin, J., Poole, J., and Linzer, D. I. H. (1997) Endocrinology 138, 541–549
14. Müller, H., Ishimura, R., Orwig, K. E., Liu, B., and Soares, M. J. (1998) Biol. Reprod. 58, 45–51
15. Roby, K. F., Deb, S., Gibson, G., Szipier, C., Levan, G., Kwok, S. M. C., and Soares, M. J. (1993) J. Biol. Chem. 268, 3136–3142
16. Shaw-Bruha, C. M., Pennington, K. L., and Shull, J. D. (1998) Biochim. Biophys. Acta 1442, 304–313
17. Jabbour, H. N., Critchley, H. O., and Boddy, S. C. (1998) J. Clin. Endocrinol. Metab. 83, 2545–2553
18. Jabbour, H. N., and Critchley, H. O. D. (2001) Reproduction 123, 197–205
19. Tessier, C., Prignet-Tessier, A., Ferguson-Gottschall, S., Gu, Y., and Gabor, G. (2001) Endocrinology 142, 4086–4094
20. Rasmussen, C. A., Hashizume, K., Orwig, K. E., Xu, L., and Soares, M. J. (1996) Endocrinology 137, 5558–5566
21. Amin, R., Konno, T., Ho-Chen, J. K., and Soares, M. J. (2006) Mamm. Genome 17, 858–877
22. Amin, R., Dai, G., Dunmore, J. H., Godwin, A. R., and Soares, M. J. (2004) Proc. Natl. Acad. Sci. U. S. A. 101, 16543–16548
23. Alm, S. M. K., Konno, T., Dai, G., Lu, L., Wang, D., Dunmore, J. H., Godwin, A. R., and Soares, M. J. (2007) Development 134, 407–415
24. Soares, M. J. (2004) Reprod. Biol. Endocrinol. 2, 51
25. Jackson, D., Volpert, O. V., Bouck, N., and Linzer, D. I. H. (1994) Science 266, 1351–1354
26. Lin, J., and Linzer, D. I. H. (1999) J. Biol. Chem. 274, 21485–21489
27. Müller, H., Liu, B., Croy, B. A., Hunt, J. S., Dai, G., and Soares, M. J. (1999) Endocrinology 140, 2711–2720
28. Wang, D., Ishimura, R., Walia, D. S., Müller, H., Dai, G., Hunt, J. S., Lee, N. A., Lee, J. J., and Soares, M. J. (2000) Endocrinology 167, 15–28
29. Prignet-Tessier, A., Tessier, C., Hirotsawa-Takamori, M., Boyer, C., Ferguson-Gottschall, S., and Gibson, G. (1999) J. Biol. Chem. 274, 37982–37989
30. Kimura, F., Takakura, K., Takayashiki, K., Ishikawa, H., Goto, S., and Noda, Y. (2001) J. Biol. Chem. 276, 101, 426–432
31. Croze, F., Kennedy, T. G., Schroetter, I. C., and Friesen, H. G. (1990) Endocrinology 137, 5511–5517
32. Hiraoka, Y., Ogawa, M., Sakai, Y., Takeuchi, Y., Komatsu, M., Shiozawa, M., Tanabe, K., and Aiso, S. (1999) Biochim. Biophys. Acta 1447, 291–297
33. Toft, D. J., and Linzer, D. I. H. (1999) Endocrinology 140, 5095–5101
34. Ishibashi, K., and Imai, M. (1999) Biochem. Biophys. Res. Commun. 262, 575–578
35. Dai, G., Wang, D., Liu, B., Kasik, J. W., Müller, H., White, R. A., Hummel, G. S., and Soares, M. J. (2000) J. Endocrinol. 166, 63–75
36. Shaw-Bruha, C. M., Pennington, K. L., and Shull, J. D. (1998) Biochim. Biophys. Acta 1442, 304–313
37. Jabbour, H. N., Critchley, H. O., and Boddy, S. C. (1998) J. Clin. Endocrinol. Metab. 83, 2545–2553
38. Jabbour, H. N., and Critchley, H. O. D. (2001) Reproduction 123, 197–205
39. Tessier, C., Prignet-Tessier, A., Ferguson-Gottschall, S., Gu, Y., and Gabor, G. (2001) Endocrinology 142, 4086–4094
40. Rasmussen, C. A., Hashizume, K., Orwig, K. E., Xu, L., and Soares, M. J. (1996) Endocrinology 137, 5558–5566
41. Amin, R., Konno, T., Canham, L. N., and Soares, M. J. (2004) Proc. Natl. Acad. Sci. U. S. A. 101, 1058–1063
42. Lebakken, C. S., and Rapraeger, A. C. (1996) J. Cell Biol. 132, 1209–1221
43. Müller, H., Dai, G., and Soares, M. J. (1998) J. Histochem. Cytochem. 46, 18967
PLP-J, a Decidual Heparin-binding Cytokine

737–743
47. Müller, H., and Soares, M. J. (2006) Methods Mol. Med. 122, 331–340
48. Deb, S., Hashizume, K., Boone, K., Southard, J. N., Talamantes, F., Rawitch, A., and Soares, M. J. (1989) Mol. Cell. Endocrinol. 63, 45–56
49. Deb, S., Youngblood, T., Rawitch, A., and Soares, M. J. (1989) J. Biol. Chem. 264, 14348–14353
50. Konno, T., Rempel, L. A., Arroyo, J. A., and Soares, M. J. (2007) Biol. Reprod. 76, 709–718
51. Ain, R., Canham, L. N., and Soares, M. J. (2003) Dev. Biol. 260, 176–190
52. Faria, T. N., Deb, S., Kwok, S. C. M., Talamantes, F., and Soares, M. J. (1990) Dev. Biol. 141, 279–291
53. Lidholt, K., Weinke, J. L., Kiser, C. S., Lugenva, F. N., Bame, K. J., Cheifetz, S., Massague, J., Lindahl, U., and Esko, J. D. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 2267–2271
54. Ali, S., Edery, M., Pellegrin, I., Lesueur, L., Paly, J., Djiane, J., and Kelly, P. A. (1992) Mol. Endocrinol. 6, 1242–1248
55. Najam, S., Gibbs, R. V., Gordon, M. Y., and Rider, C. C. (1997) Cytokine 9, 1013–1022
56. Kireeva, M. L., Mo, F. E., Yang, G. P., and Lau, L. F. (1996) Mol. Cell. Biol. 16, 1326–1334
57. Soares, M. J., De, M., Pinal, C. S., and Hunt, J. S. (1989) Biol. Reprod. 40, 435–447
58. Hamlin, G. P., and Soares, M. J. (1995) Endocrinology 136, 322–331
59. Heiberger, R. M., and Holland, B. (2004) Statistical Analysis and Data Display: An Intermediate Course with Examples in S-Plus, R, and SAS, Springer, New York
60. Rapraeger, A. C. (2001) Semin. Cell Dev. Biol. 12, 107–116
61. Morgan, M. R., Humphries, M. J., and Bass, M. D. (2007) Nat. Rev. Mol. Cell. Biol. 8, 957–969
62. Cooke, N. E., and Liebhaber, S. A. (1995) Vitam. Horm. 50, 385–459
63. Khurana, S., Kuns, R., and Ben-Jonathan, N. (1999) Endocrinology 140, 1026–1029
64. Bishop, J. R., Schuksz, M., and Esko, J. D. (2007) Nature 446, 1030–1037
65. Kruse, A., Martens, N., Fernekorn, U., Hallmann, R., and Butcher, E. C. (2002) Biol. Reprod. 66, 333–345
66. Rapraeger, A. (2000) J. Cell Biol. 149, 995–997
67. Tkachenko, E., Rhodes, J. M., and Simons, M. (2005) Circulation Res. 96, 488–500
68. Greca, C. D. S., Nader, H. B., Dietrich, C. P., Abrahamsohn, A., and Zorn, T. M. T. (2000) Anat. Rec. 259, 413–423